Rib-X Pharmaceuticals, Inc. to Present at 10th Annual Superbugs & Superdrugs Conference
— Company to present interim results from Phase 2 trial of novel compound RX-1741
New Haven, Connecticut. April 3, 2008 — Rib-X Pharmaceuticals, Inc.,
a development-stage company focused on the discovery and development of novel antibiotics
for the treatment of antibiotic-resistant infections, today announced that Albert Collinson,
Ph.D., Chief Business Officer, will be presenting at the 10th Annual Superbugs & Superdrugs
Conference on April 9, 2008 in London, U.K. Dr. Collinson will disclose interim results from
Rib-X's Phase 2 clinical trial of RX-1741 in the treatment of uncomplicated Skin and Soft Tissue
Infections (uSSTI).
RX-1741 was discovered using Rib-X's proprietary computational tools and knowledge of the three-dimensional structure of the 50S subunit of the ribosome. An oxazolidinone antibiotic that exhibits activity against methicillin resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, RX-1741 has demonstrated both wider spectrum and stronger potency of activity than Zyvox® (linezolid), the only currently marketed product in this compound class.
The uSSTI study will enroll approximately 150 patients in study centers across the U.S. The Company intends to release final data from all patients during the first half of 2008.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
RX-1741 was discovered using Rib-X's proprietary computational tools and knowledge of the three-dimensional structure of the 50S subunit of the ribosome. An oxazolidinone antibiotic that exhibits activity against methicillin resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, RX-1741 has demonstrated both wider spectrum and stronger potency of activity than Zyvox® (linezolid), the only currently marketed product in this compound class.
uSSTI Study Design
The uSSTI study is a Phase 2, multicenter, randomized, open-label, comparative study to evaluate
the safety and efficacy of RX-1741 versus linezolid in the outpatient treatment of adults with uSSTI.
The study assesses the efficacy, safety and tolerability of a once or twice daily dose of RX-1741
compared to a twice daily dose of linezolid. Dosing is given for five to ten days for the
treatment of ambulatory patients with uSSTI.
The uSSTI study will enroll approximately 150 patients in study centers across the U.S. The Company intends to release final data from all patients during the first half of 2008.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |